hero image
Webinar

MRD as a tool to evaluate treatment response and predict relapse in Ph+ ALL

Upcoming
icon_0085_cc_gen_calendar-s
Sep 19, 2026
icon_0175_ls_qf_operating_hours-s
7:59 AM (GMT+0)

About this webinar

Measurable residual disease (MRD) represents the most reliable marker to predict outcome and guide therapeutic decisions in management of acute lymphoblastic leukemia (ALL) in both children and adults. In Philadelphia-positive (Ph+) ALL, molecular MRD assessment relies on two markers, the oncogenic fusion BCR::ABL1 and the genomic clono-specific immunoglobulin and T-cell receptor (IG/TR). In his presentation, Dr. Rathana Kim reviews the methodologies and clinical settings that use both approaches in the modern therapy era.

Speakers

Fill out the form to take part in the event